In the Claims:

Claims 2 and 3 are cancelled.

Claims 1, 4-15 are pending

1) (currently amended) A method of treating a human patient with cancer who has received an allogeneic hematopoietic cell transplant by controlling a GVL effect, comprising administering to said patient ~~animal~~ an amount of beclomethasone 17, 21-diproprionate effective to prevent or reduce symptoms of GVHD wherein the administration leads to less prednisone exposure while maintaining a GVL reaction effective to eliminate or reduce the number of cancer cells in the blood of said patient ~~animal~~.

2) (cancelled)

3) (cancelled)

4) (previously presented) The method of claim 1, wherein the beclomethasone 17, 21-diproprionate is administered orally at a dosage of between about 0.1 mg per day to about 8 mg per day.

5) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered orally at a dosage of between about 2 mg per day to about 4 mg per day.

6) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered orally from day 1 to about day 80 following hematopoietic cell transplantation.

7) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered in combination with prednisone or prednisolone at a concentration of at least 1 mg/kg body weight/day.

8) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is formulated for oral administration in the form of a pill, tablet, capsule or microsphere.

9) (previously presented) The method of claim 8 wherein the beclomethasone 17, 21-diproprionate is formulated such that the pill, microsphere, or capsule dissolves in the stomach, small intestine or colon.

10) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is formulated for oral administration in the form of an emulsion.

11) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered following infusion of the hematopoietic cells.

12) (previously presented) The method of claim 1 wherein administration of the beclomethasone 17, 21-diproprionate ceases after 80 days following infusion of the hematopoietic cells.

13) (previously presented) The method of claim 1 wherein the patient has received an allogeneic bone marrow transplant.

14) (previously presented) The method of claim 1 wherein the patient has received an allogeneic blood transplant.

15) (previously presented) The method of claim 1 wherein the beclomethasone 17, 21-diproprionate is administered in combination with at least one of cyclosporine, methotrexate, tacrolimus, anti-lymphocyte globulin, anti T-cell monoclonal antibodies and anti T-cell immunotoxins.